|Articles|January 1, 2001

January 2001
Volume 7
Issue 1

The Employer's Perspective

Author(s)Donald S. Shepard, PhD

Download PDF: The Employer's Perspective

Articles in this issue

over 25 years ago

Article

Indirect Cost of Ischemic Heart Disease to Employers

over 25 years ago

Article

Disenrollment from Medicare HMOs

over 25 years ago

Article

A Comparison of Abciximab Use in MCO and Non-MCO Populations

over 25 years ago

Article

Drugs and the Elderly, Part 2: Strategies for Improving Prescribing in a Managed Care Environment

over 25 years ago

Article

Ambulatory Drug Utilization Review: Opportunities for Improved Prescription Drug Use

over 25 years ago

Article

Can Administrative Database Studies Inform Medication Use Policy Decisions? An Application of Occam's Razor

over 25 years ago

Article

Is the Healthcare Workforce a Barrier to Cost Containment?

over 25 years ago

Article

Is the Healthcare Workforce a Barrier to Cost Containment?

over 25 years ago

Article

Is the Healthcare Workforce a Barrier to Cost Containment?

over 25 years ago

Article

Is the Healthcare Workforce a Barrier to Cost Containment?

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

ByOnur Baser, PhD, MS,Heidi C. Waters, PhD,Nehir Yapar, BS,Gabriela Samayoa, MD, MPH,Xue Han, PhD,Deborah Freedman, MBA,Lauren Isenman, MPH,Rashmi Patel, MD, PhD

June 12th 2026

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

ByJason Bartock, MD,Adam Green, MD,Raquel Nahra, MD,Amy Bordogna, MD,Amir Davoodi, MD,Jean-Sebastien Rachoin, MD

June 11th 2026

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

ByDana R. Fletcher, PhD,Lisa M. Sandy, MA,Joy Waughtal, MPH,Cole Hoffman, MS,Sylvie Novins-Montague, BA,Patrick Hosokawa, MS,Pamela N. Peterson, MD, MSPH,Larry A. Allen, MD, MPH,Sheana Bull, PhD,P. Michael Ho, MD, PhD

June 10th 2026

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

ByRazanne Oueini, PharmD,Ben Shirley, BS,Christie Teigland, PhD,Melissa Castora-Binkley, PhD, MA,Scott Bilder, PhD,Kiran Sunkari, MS,Lynn Pezzullo, RPh

June 8th 2026

US map with stethoscope | Image Credit: © Andreas Prott - stock.adobe.com

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

ByShifeng Wu, MM

June 5th 2026

The Employer's Perspective

Articles in this issue

Related Content

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

Trending on AJMC

ATTR-CM Incidence, Prevalence Rose Sharply in the US

CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes

First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention

Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC

Natera's Moshkevich Discusses TOMR Approach and the Future of MRD-Guided Care

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

The Employer's Perspective

Articles in this issue

Related Content

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

Trending on AJMC

ATTR-CM Incidence, Prevalence Rose Sharply in the US

CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes

First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention

Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC

Natera's Moshkevich Discusses TOMR Approach and the Future of MRD-Guided Care